Product Description
Mechanisms of Action: ACHE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Injection
FDA Designation: *
Approval Status: Approved
Approved Countries: Colombia | Germany | India | Indonesia | New Zealand | Pakistan | Peru | Philippines | Portugal | Taiwan | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Ocugenix Corporation
Company Location: Eastern America
Company Founding Year: 2020
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Neovascular age-related macular degeneration|Wet Macular Degeneration
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05904691 |
OCU-10-C-110-CS101 | P1 |
Recruiting |
Neovascular age-related macular degeneration|Wet Macular Degeneration |
2026-11-30 |
50% |
2025-03-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/10/2026 |
News Article |
Cognex Announces Participation at Upcoming Investor Conferences |
|
01/15/2026 |
News Article |
Cognex Announces Fourth Quarter 2025 Earnings Release and Conference Call Dates |
|
01/08/2026 |
News Article |
Machine Vision Camera Market worth $10.19 billion by 2030 - Exclusive Report by MarketsandMarkets™ |
|
12/01/2025 |
News Article |
Cognex Announces Participation at Upcoming Investor Conferences |